Tara E Soumerai
Overview
Explore the profile of Tara E Soumerai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
2075
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Soumerai T, Mulvey T, Jackson V, Lennes I
Cancer J
. 2024 Jan;
30(1):27-30.
PMID: 38265923
Delivering oncologic care via telemedicine has presented a unique set of benefits and challenges. Discussions of sensitive topics between patients and providers can be difficult on a virtual platform. Although...
2.
Soumerai T, Cote G, Goiffon R, Yerevanian A, Sy A
N Engl J Med
. 2023 Jun;
388(26):2467-2477.
PMID: 37379139
No abstract available.
3.
Zubiri L, Rosovsky R, Mooradian M, Piper-Vallillo A, Gainor J, Sullivan R, et al.
Oncologist
. 2021 May;
26(8):e1427-e1433.
PMID: 33932247
Background: The coronavirus disease 2019 (COVID-19) pandemic has significantly impacted health care systems. However, to date, the trend of hospitalizations in the oncology patient population has not been studied, and...
4.
Reynolds K, Klempner S, Parikh A, Hochberg E, Michaelson M, Mooradian M, et al.
Oncologist
. 2020 Jul;
25(11):997-1000g.
PMID: 32697887
No abstract available.
5.
Soumerai T, Kamdar M, Chabner B
Oncologist
. 2019 Mar;
24(5):574-575.
PMID: 30819784
The cause of drug shortages is a complex issue. This commentary highlights the shortage of intravenous opioid medications for cancer patients, in light of the opioid overdose epidemic.
6.
Soumerai T, Donoghue M, Bandlamudi C, Srinivasan P, Chang M, Zamarin D, et al.
Clin Cancer Res
. 2018 Aug;
24(23):5939-5947.
PMID: 30068706
Purpose: Advanced-stage endometrial cancers have limited treatment options and poor prognosis, highlighting the need to understand genetic drivers of therapeutic vulnerabilities and/or prognostic predictors. We examined whether prospective molecular characterization...
7.
Zehir A, Benayed R, Shah R, Syed A, Middha S, Kim H, et al.
Nat Med
. 2017 Aug;
23(8):1004.
PMID: 28777785
No abstract available.
8.
Hyman D, Smyth L, Donoghue M, Westin S, Bedard P, Dean E, et al.
J Clin Oncol
. 2017 May;
35(20):2251-2259.
PMID: 28489509
Purpose AKT1 E17K mutations are oncogenic and occur in many cancers at a low prevalence. We performed a multihistology basket study of AZD5363, an ATP-competitive pan-AKT kinase inhibitor, to determine...
9.
Zehir A, Benayed R, Shah R, Syed A, Middha S, Kim H, et al.
Nat Med
. 2017 May;
23(6):703-713.
PMID: 28481359
Tumor molecular profiling is a fundamental component of precision oncology, enabling the identification of genomic alterations in genes and pathways that can be targeted therapeutically. The existence of recurrent targetable...
10.
Grisham R, Sylvester B, Won H, McDermott G, DeLair D, Ramirez R, et al.
J Clin Oncol
. 2015 Sep;
33(34):4099-105.
PMID: 26324360
Purpose: No effective systemic therapy exists for patients with metastatic low-grade serous (LGS) ovarian cancers. BRAF and KRAS mutations are common in serous borderline (SB) and LGS ovarian cancers, and...